

ELECTRONIC SUPPLEMENTARY INFORMATION (ESI)

An Integrated ESI-MS/EPR/Computational Characterization of the Binding of Metal Species to Proteins: Vanadium Drugs–Myoglobin Application †

Giuseppe Sciortino,^{a,b} Daniele Sanna,^{*c} Valeria Ugone,^a Jean-Didier Maréchal,^{*b} and Eugenio Garribba,^{*a}

^a *Dipartimento di Chimica e Farmacia, Università di Sassari, Via Vienna 2, I-07100 Sassari, Italy. E-mail: garribba@uniss.it; Tel: +39 079 229487.*

^b *Departament de Química, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Barcelona, Spain. Jeandidier.Marechal@uab.cat; Tel: +34 935814936.*

^c *Istituto CNR di Chimica Biomolecolare, Trav. La Crucca 3, I-07040 Sassari, Italy. E-mail: daniele.sanna@icb.cnr.it; Tel: +39 079 2841207.*

* Corresponding authors.

Table S1 Species identified in the ESI-MS spectra of the system V^{IV}O²⁺/L-mimosinate.

Ion	Composition	Exptl m/z ^a	Calcd m/z ^a	Error (ppm) ^b
[VO(mim) ₂ +H] ⁻	C ₁₆ H ₁₇ N ₄ O ₉ V	460.04490	460.04407	1.8
[VO(mim) ₂] ²⁻	C ₁₆ H ₁₆ N ₄ O ₉ V	229.51825	229.51839	-0.6
[VO(mim) ₂ (OH)+2H] ⁻	C ₁₆ H ₁₇ N ₄ O ₁₀ V	476.03973	476.03898	1.6
[VO(mim) ₂ +2H] ⁻	C ₁₆ H ₁₈ N ₄ O ₁₀ V	477.04744	477.04680	1.2

^a The experimental and calculated m/z values refer to the monoisotopic representative peak. ^b Deviation in ppm from the calculated values, calculated as $10^6 \times [(\text{Exptl m/z} - \text{Calcd m/z})/\text{Calcd m/z}]$.

Table S2 ^{51}V hyperfine coupling constants calculated at the level of theory BHandHLYP/6-311+g(d) for the possible bis-chelated $\text{V}^{\text{IV}}\text{O}$ complexes formed by L-mimosinate.^a

Complex	A_x^{calcd}	A_y^{calcd}	A_z^{calcd}	A_z^{exptl}	PD ^b
<i>SPY-5-12</i>	-48.75	-57.32	-158.2	-169.1	-6.4
<i>SPY-5-13</i>	-48.53	-57.59	-158.0	-169.1	-6.5
<i>OC-6-32</i>	-59.17	-63.54	-163.8	-169.1	-3.1
<i>OC-6-23</i>	-57.37	-62.77	-162.9	-169.1	-3.7
<i>OC-6-34</i> ^c	-60.51	-64.32	-164.6	-169.1	-2.6
<i>OC-6-24</i> ^c	-59.40	-63.48	-164.4	-169.1	-2.8

^a All the A values are reported in 10^{-4} cm^{-1} . ^b Percent deviation (PD) with respect to the absolute experimental value calculated as: $100 \times [(|A_z|^{\text{calcd}} - |A_z|^{\text{exptl}})/|A_z|^{\text{exptl}}]$. ^c With boldface text the most probable isomers are shown.

Table S3 Docking solutions for the interaction of VO(acac)⁺ with myoglobin.

Site	Residues	V-D ^a	<i>F</i> _{max} ^b	<i>F</i> _{mean} ^c	Pop. ^d
1 st	His24; His119	2.108, 2.440	44.8	42.6	92%
2 nd	His82; Asp141	2.180, 2.452	34.5	30.7	64%
3 rd	Glu83; Asp141	2.181, 2.406	38.7	36.8	94%
4 th	His116; Gln124	2.683, 2.174	32.8	31.9	52%

^a Distance in Å; D = N, O. ^b *Fitness* value for the most stable pose of each cluster (*F*_{max}). ^c Mean *Fitness* value of the GoldScore scoring function for each cluster (*F*_{mean}). ^d Percent population of the cluster.




Fig. S1 ESI-MS spectra recorded in the systems: (a) Mb; (b) [VO(dhp)₂]/Mb; (c) *cis*-[VO(mim)₂(H₂O)]²⁻/Mb; (d) *cis*-[VO(ma)₂(H₂O)]/Mb; (e) [VO(acac)₂]/Mb. Mb concentration was 5 μM and molar ratio V/Mb was 3/1.




Fig. S2 Deconvoluted ESI-MS spectrum of myoglobin (concentration 5 μ M). Mass is expressed in Da.





Fig. S3 Zoom of the multiplex with charge +9 of (a) Mb and (b) system [VO(dhp)₂]/Mb. Mb concentration was 5 μM and molar ratio V/Mb was 3/1. The most intense peak due to the adducts [VO(dhp)⁺]-Mb and [VO(dhp)₂]-Mb are indicated.




Fig. S4 Ultrazoom of the two most intense peaks with charge +9 detected in the systems: (a) Mb; (b) [VO(dhp)₂]/Mb; (c) *cis*-[VO(mim)₂(H₂O)]²⁺/Mb; (d) *cis*-[VO(ma)₂(H₂O)]/Mb; (e) [VO(acac)₂]/Mb. Mb concentration was 5 μM and molar ratio V/Mb was 3/1.




Fig. S5 Most stable adducts predicted by docking methods for the interaction of the VO(dhp)⁺ moiety with myoglobin: a) *SPY-5-13-A-VO(dhp)(H₂O)₂* with His24 and His119; b) *SPY-5-13-C-VO(dhp)(H₂O)₂* with His82 and Asp141 and c) *SPY-5-13-C-VO(dhp)(H₂O)₂* with Glu83 and Asp141.




Fig. S6 Experimental (above) and calculated (below) isotopic pattern for the peak of $[\text{VO}(\text{mim})_2]^{2-}$ revealed at $m/z = 229.5$ in the negative ESI-MS spectrum recorded on the system $\text{V}^{\text{IV}}\text{O}^{2+}/\text{mim}$ 1/2 (V concentration 50 μM).




Fig. S7 Deconvoluted ESI-MS spectra recorded on the system containing $\text{VO}(\text{ma})_2$ and myoglobin (50 μM): molar ratio 3/1 (top), 5/1 (centre) and 10/1 (bottom). With **a** and **b** the fragments $\text{VO}(\text{ma})^+$ and $\text{VO}(\text{ma})_2$ are indicated. Mass is expressed in Da.




Fig. S8 Deconvoluted ESI-MS spectra recorded on the system containing $[\text{VO}(\text{acac})_2]$ and myoglobin ($50 \mu\text{M}$): molar ratio 3/1 (top) and 5/1 (bottom). With **a** and **b** the fragments $\text{VO}(\text{acac})^+$ and $\text{VO}(\text{acac})_2$ are indicated. Mass is expressed in Da.




Fig. S9 High field region of the X-band anisotropic EPR spectra recorded on frozen solutions (120 K) containing: a) $V^{IV}O^{2+}/acac/MeIm$ 1/2/4; b) $V^{IV}O^{2+}/acac/Mb$ 1/2/1; c) $V^{IV}O^{2+}/acac/Mb$ 2/4/1; d) $V^{IV}O^{2+}/acac/Mb$ 4/8/1; e) $V^{IV}O^{2+}/acac/Mb$ 6/12/1; f) $V^{IV}O^{2+}/acac/Mb$ 8/16/1; g) $V^{IV}O^{2+}/acac/Mb$ 10/20/1 and h) $V^{IV}O^{2+}/acac$ 1/2. $V^{IV}O^{2+}$ concentration was 1.0×10^{-3} M. **I** and the dash-dotted lines indicate the $M_1 = 7/2$ resonance of the species $[VO(acac)_2]$.




Fig. S10 High field region of the X-band isotropic EPR spectra recorded on aqueous solutions (298 K) containing: a) $V^{IV}O^{2+}/acac$ 1/2 and b) $V^{IV}O^{2+}/acac/Mb$ 1/2/1. $V^{IV}O^{2+}$ concentration was 1.0×10^{-3} M. **I** and the dash-dotted line indicate the $M_1 = -7/2$ and $7/2$ resonances of the species $[VO(acac)_2]$.







Fig. S11 Cluster distribution for the interaction of $[\text{VO}(\text{acac})_2]$ with myoglobin. The six clusters are represented with different colors.



Scheme S1 Structures in aqueous solution and physiological pH of the bis-chelated $V^{IV}O$ complexes formed by 1,2-dimethyl-3-hydroxy-4(1*H*)-pyridinonate, L-mimosinate, maltolate and acetylacetonate.



Scheme S2 Enantiomers of $[\text{VO}(\text{dhp})(\text{H}_2\text{O})_2]^+$ (above) and $[\text{VO}(\text{ma})(\text{H}_2\text{O})_2]^+$ (below).



Scheme S3 Possible isomers of the bis-chelated $V^{IV}O$ complex formed by L-mimosinate.